EWS-FLI1 and Ewing's sarcoma: Recent molecular data and new insights

Cancer Biology and Therapy

Volumn 1, Issue 4, 2002, Pages 329-335

  Ladanyi, Marc ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Apoptosis; p14ARF; p53; Splicing; Transcription; Translocation

Indexed keywords

EWS FLI1 FUSION PROTEIN; EWS-FLI1 FUSION PROTEIN; ONCOPROTEIN; PROTEIN P16INK4A; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FLI 1;

EWING SARCOMA; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; MUTATION; PHYSIOLOGY; REVIEW;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; HUMANS; MUTATION; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; SARCOMA, EWING'S; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 0038298371     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.1.4.2900     Document Type: Review

References (131)

1. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359:162-5.
2. Kovar H, Aryee D, Zoubek A. The Ewing family of tumors and the search for the Achilles' heel. Curr Opin Oncol 1999; 11:275-84. (Pubitemid 29312747)
3. Kim J, Pelletier J. Molecular genetics of chromosome translocations involving EWS and related family members. Physiol Genomics 1999; 1:127-38. (Pubitemid 129622460)
4. de Alava E, Gerald WL. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 2000; 18:204-13. (Pubitemid 30036354)
5. Lawlor ER, Mathers JA, Bainbridge T, Horsman DE, Kawai A, Healey JH, et al. Peripheral Primitive Neuroectodermal Tumors in Adults: Documentation by Molecular Analysis. J Clin Oncol 1998; 16:1150-7. (Pubitemid 28108752)
6. Sezer O, Jugovic D, Blohmer JU, Turzynski A, Thiel G, Langelotz C, et al. CD99 positivity and EWS-FLI1 gene rearrangement identify a breast tumor in a 60-year-old patient with attributes of the Ewings family of neoplasms. Diag Mol Pathol 1999; 8:120-4. (Pubitemid 29521902)
7. Zucman J, Melot T, Desmaze C, Ghysdael J, Plougastel B, Peter M, et al. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J 1993; 12:4481-7. (Pubitemid 23330254)
8. Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM, et al. The Ewing family of tumors - a subgroup of small-round-cell tumors defined by specific chimeric transcripts. New Engl J Med 1994; 331:294-9. (Pubitemid 24236016)
9. Sharrocks AD. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2001; 2:827-37. (Pubitemid 33674083)
10. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ets-family transcription factor, ERG. Nature Genet 1994; 6:146-51. (Pubitemid 24188594)
11. Jeon IS, Davis JN, Braun BS, Sublett JE, Roussel MF, Denny CT, et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 1995; 10:1229-34.
12. Kaneko Y, Yoshida K, Handa M, Toyoda Y, Nishihira H, Tanaka Y, et al. Fusion of an ETS-family gene, E1AF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. Genes Chromosom Cancer 1996; 15:115-21.
13. Urano F, Umezawa A, Hong W, Kikuchi H, Hata J. A novel chimera gene between EWS and E1A-F, encoding the adenovirus E1A enhancer-binding protein, in extraosseous Ewing's sarcoma. Biochem Biophys Res Commun 1996; 219:608-12. (Pubitemid 26090913)
14. Peter M, Couturier J, Pacquement H, Michon J, Thomas G, Magdelenat H, et al. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene 1997; 14:1159-64. (Pubitemid 27141917)
15. Laudet V, Hanni C, Stehelin D, Duterque-Coquillaud M. Molecular phylogeny of the ETS gene family. Oncogene 1999; 18:1351-9. (Pubitemid 29094887)
16. Truong AH, Ben David Y. The role of Fli-1 in normal cell function and malignant transformation. Oncogene 2000; 19:6482-9. (Pubitemid 32108438)
17. Vlaeminck-Guillem V, Carrere S, Dewitte F, Stehelin D, Desbiens X, Duterque-Coquillaud M. The Ets family member Erg gene is expressed in mesodermal tissues and neural crests at fundamental steps during mouse embryogenesis. Mech Dev 2000; 91:331-5. (Pubitemid 30125933)
18. Ladanyi M. The emerging molecular genetics of sarcoma translocations. Diag Mol Pathol 1995; 4:162-73.
19. Sorensen PH, Triche TJ. Gene fusions encoding chimaeric transcription factors in solid tumours. Semin Cancer Biol 1996; 7:3-14. (Pubitemid 26132191)
20. Labelle Y, Zucman J, Stenman G, Kindblom LG, Knight J, Turc-Carel C, et al. Oncogenic conversion of a novel orphan nuclear receptor by chromosome translocation. Hum Mol Genet 1995; 4:2219-26.
21. Clark J, Benjamin H, Gill S, Sidhar S, Goodwin G, Crew J, et al. Fusion of EWS gene to CHN, a member of the steroid/thyroid receptor gene superfamily, in a human myxoid chondrosarcoma. Oncogene 1996; 12:229-35. (Pubitemid 26042560)
22. Panagopoulos I, Hoglund M, Mertens F, Mandahl N, Mitelman F, Aman P. Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene 1996; 12:489-94. (Pubitemid 26059642)
23. Ohno T, Ouchida M, Lee L, Gatalica Z, Rao VN, Reddy ES. The EWS gene, involved in Ewing family of tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors, codes for an RNA binding protein with novel regulatory domains. Oncogene 1994; 9:3087-97. (Pubitemid 24296791)
24. Morohoshi F, Arai K, Takahashi EI, Tanigami A, Ohki M. Cloning and mapping of a human RBP56 gene encoding a putative RNA binding protein similar to FUS/TLS and EWS proteins. Genomics 1996; 38:51-7. (Pubitemid 26423913)
25. Bertolotti A, Lutz Y, Heard DJ, Chambon P, Tora L. hTAFII68, a novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II. EMBO J 1996; 15:5022-31. (Pubitemid 26315812)
26. Morohoshi F, Ootsuka Y, Arai K, Ichikawa H, Mitani S, Munakata N, Ohki M. Genomic structure of the human RBP56/hTAFII68 and FUS/TLS genes. Gene 1998; 221:191-8. (Pubitemid 29023746)
27. Aman P, Panagopoulos I, Lassen C, Fioretos T, Mencinger M, Toresson H, et al. Expression patterns of the human sarcoma-associated genes FUS and EWS and the genomic structure of FUS. Genomics 1996; 37:1-8. (Pubitemid 26341827)
28. Plougastel B, Zucman J, Peter M, Thomas G, Delattre O. Genomic structure of the EWS gene and its relationship to EWSR1, a site of tumor-associated chromosome translocation. Genomics 1993; 18:609-15. (Pubitemid 24021079)
29. May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, Delattre O, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A 1993; 90:5752-6. (Pubitemid 23176240)
30. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB, et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 1993; 13:7393-8. (Pubitemid 23354263)
31. Ouchida M, Ohno T, Fujimura Y, Rao VN, Reddy ES. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene 1995; 11:1049-54.
32. Kovar H, Aryee DN, Jug G, Henockl C, Schemper M, Delattre O, et al. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 1996; 7:429-37. (Pubitemid 26362087)
33. Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y. EWS-FLI1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 1997; 99:239-47. (Pubitemid 27053464)
34. Lambert G, Bertrand JR, Fattal E, Subra F, Pinto-Alphandary H, Malvy C, et al. EWS fli-1 antisense nanocapsules inhibits Ewing sarcoma-related tumor in mice. Biochem Biophys Res Commun 2000; 279:401-6. (Pubitemid 32016729)
35. Athanasiou M, LeGallic L, Watson DK, Blair DG, Mavrothalassitis G, et al. Suppression of the Ewing's sarcoma phenotype by FLI1/ERF repressor hybrids. Cancer Gene Ther 2000; 7:1188-95. (Pubitemid 30661037)
36. Ohno T, Rao VN, Reddy ES. EWS/FLI-1 chimeric protein is a transcriptional activator. Cancer Res 1993; 53:5859-63. (Pubitemid 24006149)
37. Bailly RA, Bosselut R, Zucman J, Cormier F, Delattre O, Roussel M, et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 1994; 14:3230-41. (Pubitemid 24132736)
38. Mao X, Miesfeldt S, Yang H, Leiden JM, Thompson CB. The FLI-1 and chimeric EWS-FLI-1 oncoproteins display similar DNA binding specificities. J Biol Chem 1994; 269:18216-22. (Pubitemid 24206223)
39. Pereira R, Quang CT, Lesault I, Dolznig H, Beug H, Ghysdael J. FLI-1 inhibits differentiation and induces proliferation of primary erythroblasts. Oncogene 1999; 18:1597-608. (Pubitemid 29108060)
40. Braun BS, Frieden R, Lessnick SL, May WA, Denny CT. Identification of target genes for the Ewing's sarcoma EWS/FLI fusion protein by representational difference analysis. Mol Cell Biol 1995; 15:4623-30.
41. May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. EWS/FLI1- induced manic fringe renders NIH 3T3 cells tumorigenic. Nat Genet 1997; 17:495-7. (Pubitemid 27518406)
42. Arvand A, Bastians H, Welford SM, et al. EWS/FLI1 up regulates mE2-C, a cyclin-selective ubiquitin conjugating enzyme involved in cyclin B destruction. Oncogene 1998; 17:2039-45. (Pubitemid 28499330)
43. Zwerner JP, May WA. PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors. Oncogene 2001; 20:626-33. (Pubitemid 32156187)
44. Hahm KB, Cho K, Lee C, Im YH, Chang J, Choi SG, et al. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet 1999; 23:222-7. (Pubitemid 29455398)
45. Lesault I, Quang CT, Frampton J, Ghysdael J. Direct regulation of BCL-2 by FLI-1 is involved in the survival of FLI-1-transformed erythroblasts. EMBO J 2002; 21:694-703. (Pubitemid 34174050)
46. Tamir A, Howard J, Higgins RR, Li YJ, Berger L, Zacksenhaus E, et al. Fli-1, an Ets-related transcription factor, regulates erythropoietin-induced erythroid proliferation and differentiation: evidence for direct transcriptional repression of the Rb gene during differentiation. Mol Cell Biol 1999; 19:4452-64. (Pubitemid 29242019)
47. Seth A, Giunta S, Franceschil C, Kola I, Venanzoni MC. Regulation of the human stress response gene GADD153 expression: role of ETS1 and FLI-1 gene products. Cell Death Differ 1999; 6:902-7. (Pubitemid 29488088)
48. Funaoka K, Shindoh M, Yoshida K, Hanzawa M, Hida K, Nishikata S. Activation of the p21(Waf1/Cip1) promoter by the ets oncogene family transcription factor E1AF. Biochem Biophys Res Commun 1997; 236:79-82. (Pubitemid 27341843)
49. Matsumoto Y, Tanaka K, Nakatani F, Matsunobu T, Matsuda S, Iwamoto Y. Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G(1)regulatory genes. Br J Cancer 2001; 84:768-75. (Pubitemid 32275649)
50. Zwerner JP, May WA. Dominant negative PDGF-C inhibits growth in Ewing family tumor cell lines. Proc Am Assoc Cancer Res 2002; 43:188.
51. Uren A, Sun CJ, Vitolo M, et al. Expresion of functional beta-PDGF receptors in Ewing's sarcoma. Proc Am Assoc Cancer Res 2002; 43:830.
52. Dauphinot L, De Oliveira C, Melot T, Sevenet N, Thomas V, Weissman BE, et al. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression. Oncogene 2001; 20:3258-65. (Pubitemid 32553678)
53. McKeon C, Thiele CJ, Ross RA, Kwan M, Triche TJ, Miser JS, et al. Indistinguishable patterns of protooncogene expression in two distinct but closely related tumors: Ewing's sarcoma and neuroepithelioma. Cancer Res 1988; 48:4307-14.
54. Im YH, Kim HT, Lee C, Poulin D, Welford S, Sorensen PH, et al. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor - type II receptor gene. Cancer Res 2000; 60:1536-40.
55. Siligan C, Spahn L, Ban J, et al. Identifying genomic targets for ES-FLI1 in-situ. Proc Am Assoc Cancer Res 2002; 43:161.
56. Zhang J, Wu L, Peebles C, et al. Cyclin D1, a potential target of the EWS-FLI1 fusion gene. Proc Am Assoc Cancer Res 2001; 42:769.
57. Hu S, Zhang J, Wu L, Triche TJ. Characterization of the molecular targets of the Ewing's tumor EWS/FLi-1 fusion gene with a tetracycline regulated inducible expression system. Proc Am Assoc Cancer Res 2002 ; 43 :17.
58. Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 2001; 7:673-9. (Pubitemid 32588022)
59. Wai DH, Schaefer KL, Schramm A, Korsching E, Van Valen F, Ozaki T, et al. Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays. Int J Oncol 2002; 20:441-51.
60. Silvany RE, Eliazer S, Wolff NC, Ilaria RL Jr. Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation. Oncogene 2000; 19:4523-30.
61. Zoubek A, Dockhorn-Dworniczak B, Delattre O, Christiansen H, Niggli F, Gatterer-Menz I, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 1996; 14:1245-51.
62. Lin PP, Brody RI, Hamelin AC, Bradner JE, Healey JH, Ladanyi M. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. Cancer Res 1999; 59:1428-32. (Pubitemid 29160104)
63. Olsen RJ, Hinrichs SH. Phosphorylation of the EWS IQ domain regulates transcriptional activity of the EWS/ATF1 and EWS/FLI1 fusion proteins. Oncogene 2001; 20:1756-64. (Pubitemid 32368021)
64. de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998; 16:1248-55. (Pubitemid 28175736)
65. Aryee DN, Sommergruber W, Muehlbacher K, Dockhorn-Dworniczak B, Zoubek A, Kovar H. Variability in gene expression patterns of Ewing tumor cell lines differing in EWS-FLI1 fusion type. Lab Invest 2000; 80:1833-44. (Pubitemid 32012752)
66. de Alava E, Panizo A, Antonescu CR, Huvos AG, Pardo-Mindan FJ, Barr FG. Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma. Am J Pathol 2000; 156:849-55. (Pubitemid 30626943)
67. Lessnick SL, Braun BS, Denny CT, May WA. Multiple domains mediate transformation by the Ewing's sarcoma EWS-FLI-1 fusion gene. Oncogene 1995; 10:423-31.
68. Jaishankar S, Zhang J, Roussel MF, Baker SJ. Transforming activity of EWS/FLI is not strictly dependent upon DNA-binding activity. Oncogene 1999; 18:5592-7.
69. Busam KJ, Iversen K, Coplan KC, Jungbluth AA. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma. Am J Surg Pathol 2001; 25:197-204. (Pubitemid 32167501)
70. Zhang D, Paley AJ, Childs G. The transcriptional repressor ZFM1 interacts with and modulates the ability of EWS to activate transcription. J Biol Chem 1998; 273:18086-91. (Pubitemid 28334724)
71. Kambach C, Walke S, Nagai K. Structure and assembly of the spliceosomal small nuclear ribonucleoprotein particles. Curr Opin Struct Biol 1999; 9:222-30. (Pubitemid 29452902)
72. Knoop LL, Baker SJ. The splicing factor U1C represses EWS/FLI-mediated transactivation. J Biol Chem 2000; 275:24865-71. (Pubitemid 30626591)
73. Deramaudt TB, Remy P, Stiegler P. Identification of interaction partners for two closely-related members of the ETS protein family, FLI and ERG. Gene 2001; 274:169-77. (Pubitemid 32817134)
74. Yang L, Embree LJ, Hickstein DD. TLS-ERG leukemia fusion protein inhibits RNA splicing mediated by serine-arginine proteins. Mol Cell Biol 2000; 20:3345-54. (Pubitemid 30243880)
75. Hallier M, Lerga A, Barnache S, Tavitian A, Moreau-Gachelin F. The transcription factor Spi-1/PU.1 interacts with the potential splicing factor TLS. J Biol Chem 1998; 273:4838-42. (Pubitemid 28108632)
76. Chansky HA, Hu M, Hickstein DD, Yang L. Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein. Cancer Res 2001; 61:3586-90. (Pubitemid 32694966)
77. Yang L, Chansky HA, Hickstein DD. EWS.Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing. J Biol Chem 2000; 275:37612-8. (Pubitemid 32004872)
78. Knoop LL, Baker SJ. EWS/FLI alters 5' splice site selection. J Biol Chem 2001; 276:22317-22.
79. Ohkura N, Yaguchi H, Tsukada T, Yamaguchi K. The EWS/NOR1 fusion gene product gains a novel activity affecting pre-mRNA splicing. J Biol Chem 2002; 277:535-43. (Pubitemid 34952089)
80. Smith CW, Valcarcel J. Alternative pre-mRNA splicing: the logic of combinatorial control. Trends Biochem Sci 2000; 25:381-8. (Pubitemid 30497249)
81. Stickeler E, Kittrell F, Medina D, Berget SM. Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene 1999; 18:3574-3582. (Pubitemid 29322382)
82. Caballero OL, de Souza SJ, Brentani RR, Simpson AJ. Alternative spliced transcripts as cancer markers. Dis Markers 2001; 17:67-75. (Pubitemid 32964838)
83. Mercatante D, Kole R. Modification of alternative splicing pathways as a potential approach to chemotherapy. Pharmacol Ther 2000; 85:237-43. (Pubitemid 30160793)
84. Rudzki Z, Jothy S. CD44 and the adhesion of neoplastic cells. Mol Pathol 1997; 50:57-71. (Pubitemid 27455005)
85. Bednarek AK, Keck-Waggoner CL, Daniel RL, Laflin KJ, Bergsagel PL, Kiguchi K, et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 2001; 61:8068-73. (Pubitemid 33091591)
86. Huerta S, Srivatsan ES, Venkatesan N, Peters J, Moatamed F, Renner S, et al. Alternative mRNA splicing in colon cancer causes loss of expression of neural cell adhesion molecule. Surgery 2001; 130:834-43. (Pubitemid 33022391)
87. Hinohara S, Satake N, Sekine K, Kaneko Y. Abnormalities of the FHIT transcripts in osteosarcoma and Ewing sarcoma. Jpn J Cancer Res 1998; 89:887-94. (Pubitemid 28486813)
88. Sidhar SK, Clark J, Gill S, Hamoudi R, Crew AJ, Gwilliam R, et al. The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet 1996; 5:1333-8. (Pubitemid 26335852)
89. Argani P, Antonescu CR, Illei PB, Lui MY, Timmons CF, Newbury R, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol 2001; 159:179-92. (Pubitemid 33704203)
90. Ladanyi M, Lui MY, Antonescu CR, Krause-Boehm A, Meindl A, Argani P, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 2001; 20:48-57.
91. Weterman MA, Wilbrink M, Geurts van Kessel A. Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)-positive papillary renal cell carcinomas. Proc Natl Acad Sci USA 1996; 93:15294-8.
92. Clark J, Lu YJ, Sidhar SK, Parker C, Gill S, Smedley D. Fusion of splicing factor genes PSF and NONO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene 1997; 15:2233-9. (Pubitemid 27493913)
93. Skalsky YM, Ajuh PM, Parker C, Lamond AI, Goodwin G, Cooper CS. PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors. Oncogene 2001; 20:178-87. (Pubitemid 32150263)
94. McGarvey T, Rosonina E, McCracken S, Li Q, Arnaout R, Mientjes E, et al. The acute myeloid leukemia-associated protein, DEK, forms a splicing-dependent interaction with exon-product complexes. J Cell Biol 2000; 150:309-20. (Pubitemid 30491355)
95. Chen W, Itoyama T, Chaganti RS. Splicing factor SRP20 is a novel partner of BCL6 in a t(3;6)(q27;p21) translocation in transformed follicular lymphoma. Genes Chromosomes Cancer 2001; 32:281-4. (Pubitemid 32953982)
96. Ma Z, Morris SW, Valentine V, Li M, Herbrick JA, Cui X, et al. Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet 2001; 28:220-1. (Pubitemid 32626023)
97. Mercher T, Coniat MB, Monni R, Mauchauffe M, Khac FN, Gressin L, et al. Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia. Proc Natl Acad Sci U S A 2001; 98:5776-9. (Pubitemid 32435718)
98. Lopez-Guerrero JA, Pellin A, Noguera R, Carda C, Llombart-Bosch A. Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. Lab Invest 2001; 81:803-14. (Pubitemid 32553402)
99. Ladanyi M, Lewis R, Jhanwar SC, Gerald W, Huvos AG, Healey JH.MDM2 and CDK4 gene amplification in Ewing's sarcoma. J Pathol 1995; 175:211-7.
100. Kovar H, Auinger A, Jug G, Aryee D, Zoubek A, Salzer-Kuntschik M, et al. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 1993; 8:2683-90. (Pubitemid 23279096)
101. Maitra A, Roberts H, Weinberg AG, Geradts J. Aberrant expression of tumor suppressor proteins in the Ewing family of tumors. Arch Pathol Lab Med 2001; 125:1207-12. (Pubitemid 32845799)
102. Abudu A, Mangham DC, Reynolds GM, Pynsent PB, Tillman RM, Carter SR, et al. Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis. Br J Cancer 1999; 79:1185-9. (Pubitemid 29087896)
103. de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, et al. Prognostic impact of p53 status in Ewing's sarcoma. Cancer 2000; 89:783-92. (Pubitemid 30658577)
104. Wei G, Antonescu CR, de Alava E, Leung D, Huvos AG, Meyers PA, Healey JH, Ladanyi M, et al. Prognostic impact of INK4A deletion in Ewing's sarcoma. Cancer 2000; 89:793-9. (Pubitemid 30658578)
105. Bardeesy N, Falkoff D, Petruzzi MJ, Nowak N, Zabel B, Adam M, et al. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 1994; 7:91-7.
106. Bardeesy N, Beckwith JB, Pelletier J. Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations. Cancer Res 1995; 55:215-19.
107. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82:1994-2004. (Pubitemid 23293979)
108. Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, Raffeld M. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 1998; 91:4677-85. (Pubitemid 28270317)
109. Antonescu CR, Tschernyavsky SJ, Decuseara R, Leung DH, Woodruff JM, Brennan MF, et al. Prognostic impact of p53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res 2001; 7:3977-87.
110. Kovar H, Auinger A, Jug G, et al. The concept of tumor cell survival factors to explain discrepant p53 mutation frequencies in primary Ewing tumors versus cell lines. Proc Am Assoc Cancer Res 1995; 36:2.
111. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999; 13:2670-7. (Pubitemid 29508554)
112. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13:2658-9.
113. Lowe SW. Activation of p53 by oncogenes. Endocr Relat Cancer 1999; 6:45-8. (Pubitemid 29197227)
114. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109:335-6.
115. Kovar H, Jug G, Printz D, Bartl S, Schmid G, Wesierska-Gadek J. Characterization of distinct consecutive phases in non-genotoxic p53-induced apoptosis of Ewing tumor cells and the rate-limiting role of caspase 8. Oncogene 2000; 19:4096-107.
116. Lawlor ER, Scheel C, Irving J, Sorensen PH. Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors. Oncogene 2002; 21:307-18. (Pubitemid 34102139)
117. Deneen B, Denny CT. Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. Oncogene 2001; 20:6731-41.
118. Lessnick SL, Dacwag CS, Golub R. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 2002; 1:393-401.
119. Kim JS, Pirnia F, Choi YH, Nguyen PM, Knepper B, Tsokos M, et al. Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint. Oncogene 2000; 19:6082-90. (Pubitemid 32039383)
120. Yee D, Favoni RE, Lebovic GS, Lombana F, Powell DR, Reynolds CP, et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest 1990; 86:1806-14.
121. Scotlandi K, Benini S, Sarti M, Serra M, Lollini PL, Maurici D, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996; 56:4570-74. (Pubitemid 26338048)
122. Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ. The insulin-like growth factor- I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997; 272:30822-27. (Pubitemid 27527522)
123. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res 2001; 61:2704-12. (Pubitemid 32685858)
124. Sturla LM, Westwood G, Selby PJ, Lewis IJ, Burchill SA/ Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma. Cancer Res 2000; 60:6160-70.
125. Westwood G, Dibling BC, Cuthbert-Heavens D, Burchill SA. Basic fibroblast growth factor (bFGF)-induced cell death is mediated through a caspase-dependent and p53-independent cell death receptor pathway. Oncogene 2002; 21:809-24. (Pubitemid 34146293)
126. Motwani M, Jung C, Sirotnak FM, She Y, Shah MA, Gonen M, et al. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res 2001; 7:4209-19. (Pubitemid 34044647)
127. Piazza F, Gurrieri C, Pandolfi PP. The theory of APL. Oncogene 2001; 20:7216-22. (Pubitemid 33105010)
128. Kovar H, Jug G, Aryee DNT, et al. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 1997; 15:2225-32. (Pubitemid 27493912)
129. Komuro H, Hayashi Y, Kawamura M, Hayashi K, Kaneko Y, Kamoshita S, et al. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. Cancer Res 1993; 53:5284-88. (Pubitemid 23333400)
130. Hamelin R, Zucman J, Melot T, Delattre O, Thomas G. p53 mutations in human tumors with chimeric EWS/FLI-1 genes. Int J Cancer 1994; 57:336-40.
131. Mangham D, Cannon A, Li X, et al. p53 overexpression in Ewing's sarcoma/primitive neuroectodermal tumour is an uncommon event. J Clin Pathol - Mol Pathol 1995; 48:M79-82.